• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 WITH SA20 AND DISTAL CATHETER; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 WITH SA20 AND DISTAL CATHETER; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FX420T
Medical Device Problem Code Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 06/19/2023
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported that a progav 2.0 (part #fx420t) in combination with a control reservoir set (part #fv049t) was implanted during a procedure performed on (b)(6) 2022.According to the complainant, the catheter of the system caused a blockage.The patient underwent a revision procedure.The complaint device will be return to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Same event as medwatch#3004721439-2023-00197.
 
Additional Manufacturer Narrative
Investigation: visual inspection: the following observations were made during the visual inspection: -reservoir twisted to the rest of the shunt system -deposits on the reservoir -small hole in the catheter between reservoir and progav® 2.0 permeability test: the test showed that the progav 2.0 shunt system is permeable.Computer control test: the computer control test showed the opening pressure of the progav 2.0, at a reference flow rate of 20 ml/h in a horizontal position of the valve, to be 16.89 cmh2o.This is not within the specified tolerance of 0 ± 3 cmh2o.An applied pressure of 0 cmh2o, with the device in the horizontal position is expected to have a resultant pressure of 0 ± 3 cmh2o.According to our results, we can detect a presence of a slowed outflow.Additionally, the shuntassistant was tested according to standard procedure in the vertical position of the valve.At a fixed opening pressure of 20 cmh2o in the vertical position, a pressure of 20 +4/-2 cmh2o is expected.The results indicated that at a reference flow of 20 ml/h in the vertical position, the shuntassistant had a pressure of 18.81 cmh2o.This is within the specified tolerance of 20 +4/-2 cmh2o.Adjustability test: the progav 2.0 was found to be adjustable to all pressure settings.The shuntassistant is a fixed pressure valve, therefore the adjustability test is inapplicable.Braking force and brake function test: the braking force of the progav 2.0 was within the specified tolerance and the brake function operated as expected.Internal inspection of product: in order to verify whether the investigated shunt system was compromised by the known risks of hydrocephalus therapy, e.G.By a build-up of natural substances (protein, blood, or tissue particles) in the cerebrospinal fluid, the valves were finally opened with a special tool.After dismantling of the valves, deposits were found in both valves.Results: for the sake of thoroughness and transparency, we would like to point out that a permeability test was already carried out after the revision at the hospital.Based on our investigation results, we have determined that there was a slower outflow in the progav 2.0 valve at the time of our investigation.Detected deposits were the cause of the slower outflow.Existing deposits in the csf can temporarily impair the function of the valve and is described as concomitant symptoms in hydrocephalus therapy.We can exclude a defect at the time of release.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.From our point of view, no further regulatory actions are required.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV 2.0 WITH SA20 AND DISTAL CATHETER
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
Manufacturer (Section G)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM   14469
Manufacturer Contact
joerg knebel
ulanenweg 2
potsdam, 14469
GM   14469
MDR Report Key17375266
Report Number3004721439-2023-00198
Device Sequence Number17072583
Product Code JXG
UDI-Device Identifier04041906136628
UDI-Public4041906136628
Combination Product (Y/N)N
Initial Reporter CountryCH
PMA/510(K) Number
K161853
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2022
Device Explanted Year2023
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source User Facility,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date (Section B) 07/21/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model NumberFX420T
Device Catalogue NumberFX420T
Device Lot Number20055514
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer07/07/2023
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 06/21/2023
Initial Report FDA Received Date07/21/2023
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured10/15/2021
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient SexUnknown
-
-